The Westaim Corporation has developed technologies in two high-potential sectors, medical nanotechnology and flat panel televisions. Westaim’s strategy is to create value for shareholders by partnering with established commercial leaders for effective market penetration of its technologies and maximum return on investment. Westaim's technology investments include iFire Technology and NUCRYST Pharmaceuticals.
iFire Technology's goal is to be the first company to produce a truly affordable large sized, flat panel high definition television. The inherent simplicity of its proprietary thick dielectric electroluminescent (TDEL) technology gives iFire a significant manufacturing cost advantage over other flat panel technologies. iFire’s flat panel TVs will meet or exceed the performance quality of the best available products, but at a price more consumers can afford.
NUCRYST Pharmaceuticals is one of the first companies to successfully launch a medical product based on nanotechnology. Advanced wound care products with the company’s SILCRYST™ coatings are sold by Smith & Nephew plc under an exclusive license in over 30 countries under its Acticoat™ trademark. NUCRYST is also developing innovative pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. The company has developed its nanocrystalline silver in a powder form for use as an active pharmaceutical ingredient, referred to as NPI 32101.
NUCRYST Pharmaceuticals completed an Initial Public Offering of common shares in 2005. The Westaim Corporation owns approximately 75 per cent of NUCRYST's outstanding shares.
144-4th Avenue SW
Calgary, AB T2P 3N4
Canada - Map
Web Site: http://www.westaim.com